A study of the effects of cilostazol on platelet function and serum lipids in patients with diabetes mellitus

Suehiro, Akira; Sugimoto, Yoshinori; Masuda, Hiroshi; Kakishita, Eizo

doi:10.1016/s0011-393x(05)80676-9

Cited by 3 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although initially used to improve claudication in patients with peripheral vascular disease (Thompson et al, 2002), cilostazol has been suggested to be useful for the prevention of vascular complications in patients with diabetes mellitus (Suehiro et al, 1993). Retinopathy is a uniquely specific and noninvasively assessable symptom of diabetic mircovascular damage, and thus may serve as a novel biomarker of vascular disease risk in asymptomatic patients with diabetes.…”

Section: Neuroprotective Effects Of Cilostazol In Diabetic Retinamentioning

confidence: 99%

Neuroprotective Effects of Cilostazol on Retinal Ganglion Cell Damage in Diabetic Rats

Jung

Kim

2013

J Pharmacol Exp Ther

View full text Add to dashboard Cite

Neurodegeneration is an important component of diabetic retinopathy, with increasing evidence that retinal ganglion cell (RGC) death occurs early in diabetes. We investigated the effects of cilostazol, which has been widely used to manage diabetic complications, on retinal ganglion cell death in the diabetic retina. Four-week-old Otsuka Long-Evans Tokushima fatty (OLETF) rats and Long-Evans Tokushima Otsuka (LETO) rats as matched nondiabetic controls were treated with daily oral cilostazol at 30 mg/kg or 0.9% saline solution. In OLETF rats at the age of 40 weeks, glial fibrillary acidic protein (GFAP) immunofluorescence staining was upregulated in vertical sections, and showed a more ramified pattern in whole-mount retinas compared with that in LETO rats. Vascular endothelial growth factor (VEGF) expression was limited to the ganglion cell layer in LETO rats, but extended into the outer plexiform layer in OLETF rats. Immunofluorescence staining and Western blotting demonstrated that cilostazol treatment reduced GFAP and VEGF expression in the retinas of OLETF rats. Terminal deoxynucleotidyl transferase-mediated terminal deoxynucleotidyl transferase-mediated digoxigenin-deoxyuridine nick-end labeling (TUNEL) staining revealed an increase in the RGC layer in OLETF compared with LETO rats (P , 0.05), and cilostazol treatment reduced the number of TUNEL-positive cells in OLETF rats (P , 0.05). Relieving retinal ischemia by systemic cilostazol treatment had a noticeable protective effect on RGCs in diabetic rats. Cilostazol treatment may be useful for the management of diabetic retinal vascular dysfunction and neuronal degeneration.

show abstract

Section: Neuroprotective Effects Of Cilostazol In Diabetic Retinamentioning

confidence: 99%